C27A7.3 Antibody

Basic Research Questions

• What is C27A7.3 and why is it significant in research?

  C27A7.3 is a protein-coding gene located on Chromosome V (position 12140876-12144293) in Caenorhabditis elegans. It has multiple transcript variants including NM_001047622.3, NM_001047623.4, NM_001269477.3, and NM_001269478.3 . The protein is significant in research due to its involvement in cellular functions related to innate immunity and cell migration pathways. Studies using C. elegans models indicate C27A7.3 may play roles in neurological function, making it relevant for research involving neurodegenerative conditions and cellular migration mechanisms.

• What control samples should be included when using C27A7.3 antibodies in flow cytometry experiments?

  For robust flow cytometry experiments with C27A7.3 antibodies, four essential controls should be included:

  • Unstained cells: To establish baseline autofluorescence

  • Negative cells: Populations not expressing C27A7.3 to confirm antibody specificity

  • Isotype control: An antibody of the same class as the C27A7.3 antibody but with no known specificity (e.g., Non-specific Control IgG, Clone X63)

  • Secondary antibody control: For indirect staining protocols, cells treated with only labeled secondary antibody to address non-specific binding

  Additionally, block non-specific binding sites using 10% normal serum from the same host species as the labeled secondary antibody, but NOT from the same host species as the primary antibody as this can lead to serious non-specific signals .

• How is C27A7.3 expression typically measured in C. elegans models?

  C27A7.3 expression in C. elegans is commonly measured using:

  • Quantitative PCR (qPCR): Using validated primers spanning exon boundaries 12-13 or 11-12 with an amplicon length of 153bp

  • Fluorescent reporter constructs: Similar to the approach used for related genes, where C27A7.1 (enpp-1) was monitored using mScarlet fluorescent protein fusion under its native promoter

  • Western blotting: Using purified antibodies against the protein, typically using protein extraction protocols optimized for C. elegans tissues

  • Immunohistochemistry: For localization studies in specific tissues

  When designing qPCR assays, researchers should target the exon boundaries shown in this reference table:

  Transcript ID	Exon Boundary	Assay Location	Amplicon Length
  NM_001047622.3	12 - 13	1711	153
  NM_001047623.4	11 - 12	1621	153
  NM_001269477.3	12 - 13	1787	153
  NM_001269478.3	11 - 12	1649	153

Advanced Research Questions

• How can C27A7.3 antibodies be validated for specificity in C. elegans research?

  Validating C27A7.3 antibodies for specificity in C. elegans research requires a multi-step approach:

  • Western blot analysis comparing wild-type and C27A7.3 mutant/RNAi-treated worms

  • Pre-absorption tests with recombinant C27A7.3 protein

  • Immunostaining patterns in tissues known to express or lack C27A7.3

  • Mass spectrometry validation of immunoprecipitated proteins

  • Cross-reactivity testing with closely related proteins

  Following similar protocols to those used for validating WDR19 orthologs in C. elegans, researchers should express recombinant C27A7.3 protein, purify it using affinity chromatography, and generate polyclonal antisera. Western blot analysis should be performed using lysate from tissues expressing the protein, comparing immune serum with pre-immune controls .

• What are the potential interactions between C27A7.3 and innate immunity pathways in C. elegans?

  Research suggests C27A7.3 may participate in innate immunity pathways in C. elegans through:

  • Possible involvement in the DAF-16 pathway, similar to related genes that influence immunity against pathogens like Pseudomonas aeruginosa

  • Potential regulation of antimicrobial peptide production

  • Interactions with insulin-like signaling pathways that regulate immunity

  Studies of related genes show that mutations can lead to susceptibility to pathogens like P. aeruginosa PA14, with hypersensitivity to Aldicarb and increased RNA levels of DAF-16 antagonists . Similar assessment methods could be applied to investigate C27A7.3, including pathogen resistance assays, quantitative RNA analysis of antimicrobial genes, and genetic interaction studies with established immunity pathway components.

• How might C27A7.3 antibodies be used to study neurodegeneration models in C. elegans?

  C27A7.3 antibodies can be strategically employed in C. elegans neurodegeneration models through:

  • Colabeling studies with neuronal markers to assess colocalization during disease progression

  • Immunoprecipitation coupled with mass spectrometry to identify protein interaction networks altered in neurodegenerative states

  • Quantitative western blotting to measure expression changes in disease models

  • In vivo tracking of protein dynamics using antibody-based imaging techniques

  Research on C. elegans Alzheimer's disease models has identified bacteria from the human microbiota that improved neuron health, with associated changes in gene expression . Similar experimental paradigms could be applied to investigate C27A7.3's potential role in neuroprotection or neurodegeneration pathways.

• What methodologies can be used to study the potential involvement of C27A7.3 in extracellular vesicle (EV) cargo in C. elegans?

  To investigate C27A7.3's potential role in EV cargo:

  • Isolate EVs using differential ultracentrifugation or size exclusion chromatography from C. elegans

  • Perform western blot analysis of EV fractions using C27A7.3 antibodies

  • Use immunogold electron microscopy to visualize C27A7.3 localization within EVs

  • Apply proteomics approaches to identify C27A7.3 interaction partners in EV fractions

  • Generate fluorescent protein-tagged C27A7.3 constructs for in vivo tracking

  Studies have successfully tracked other C. elegans proteins in EVs using mScarlet fusion constructs expressed under native promoters . Similar approaches could be adapted for C27A7.3, focusing on comparative analysis between different tissues and developmental stages.

• How can researchers interpret contradictory results when studying C27A7.3 expression across different tissues in C. elegans?

  When facing contradictory C27A7.3 expression data:

  • Verify antibody specificity using knockout/knockdown controls

  • Consider developmental stage-specific expression patterns

  • Assess potential post-translational modifications affecting antibody recognition

  • Evaluate transcript variant expression using isoform-specific primers or antibodies

  • Implement alternative detection methods (e.g., mass spectrometry) for validation

  The C27A7.3 gene produces multiple transcript variants , which may have tissue-specific expression patterns. When designing experiments, researchers should consider which specific isoforms are being targeted by their detection methods and whether developmental timing or environmental conditions might influence expression patterns.

• What approaches can be used to study potential interactions between C27A7.3 and monoclonal antibody therapies in disease models?

  To study C27A7.3 in the context of monoclonal antibody therapies:

  • Express C. elegans C27A7.3 in mammalian cell systems for antibody binding studies

  • Develop humanized C. elegans models expressing relevant human receptors

  • Use pull-down assays with therapeutic antibodies to identify potential cross-reactivity

  • Perform comparative structural analyses of C27A7.3 with human homologs

  Research on monoclonal antibody combinations like REGEN-COV has demonstrated protection against SARS-CoV-2 variants by targeting multiple epitopes simultaneously . Similar principles could be applied to develop multi-target approaches involving C27A7.3 or its mammalian homologs, particularly in neurological disease models.

• How can machine learning approaches be integrated with C27A7.3 antibody research for improved specificity prediction?

  Integrating machine learning with C27A7.3 antibody research:

  • Train neural networks on antibody-epitope binding data to predict optimal binding sites

  • Use sequence-based models like DyAb to design antibody variants with improved specificity

  • Apply computational approaches to predict cross-reactivity with related proteins

  • Implement supervised learning algorithms to identify optimal antibody combinations

  Research using the DyAb model has demonstrated success in predicting antibody affinity improvements for various targets . Similar computational approaches could be applied to optimize C27A7.3 antibody design, potentially improving specificity and reducing background in complex C. elegans tissues.